Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(SP 600125; SP-600125)
SP600125 Chemical Structure
|Product name: SP600125|
|Cat. No.: HY-12041|
SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc.
IC50 value: 40/40/90 nM(JNK1/2/3) 
in vitro: SP600125 is originally characterized as a selective ATP-competitive inhibitor of c-Jun N-terminal kinase JNK. In Jurkat T cells, SP600125 inhibits the phosphorylation of c-Jun with IC50 of 5 μM to 10 μM. In CD4+ cells, such as Th0 cells isolated from either human cord or peripheral blood, SP600125 blocks cell activation and differentiation and inhibits the expression of inflammatory genes COX-2, IL-2, IL-10, IFN-γ, and TNF-α, with IC50 of 5 μM to 12 μM . In a mouse beta cells MIN6, SP600125 (20 μM) induces the phosphorylation of p38 MAPK and its downstream CREB-dependent promoter activation . n HCT116 cells, SP600125 (20 μM) blocks the G2 phase to mitosis transition and induces endoreplication. This ability of SP600125 is independent of JNK inhibition, but due to its inhibition of CDK1-cyclin B activation upstream of Aurora A and Polo-like kinase 1 .
in vivo: In mice, SP600125 (15 mg/kg or 30 mg/kg) significantly inhibits lipopolysaccharide (LPS)-induced TNF-α expression and anti-CD3-induced apoptosis of CD4+ CD8+ thymocytes .
|M.Wt||220.23||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: ≥ 45 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||4.5407 mL||22.7035 mL||45.4071 mL|
|5 mM||0.9081 mL||4.5407 mL||9.0814 mL|
|10 mM||0.4541 mL||2.2704 mL||4.5407 mL|
Anisomycin is a pyrrolidine antibiotic, acts as an anti-fungal antibiotic which inhibits Protein Synthesis, also is a potent activator of SAPKs/JNKs.
AS601245 is an inhibitor of the c-Jun NH2-terminal kinase (JNK) (hJNK1: IC50=150nM, hJNK2: IC50=220nM and hJNK3: IC50=70 nM), has neuroprotective properties.
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
BI 78D3 is a competitive c-Jun N-terminal kinase (JNK) inhibitor with IC50 of 280 nM that displays > 100 fold selectivity over p38(alpha) and no activity at mTOR and PI-3K.
CC-930(Tanzisertib) is a selective and potent JNK1/JNK2/JNK3(IC50=61/7/6 nM) inhibitor and is currently under clinical development for fibrotic and infammatory indications.
D-JNKI-1 is a cell permeable peptide that blocks the MAPK-JNK signal pathway. The EC50 is calculated as 2.31 (mu)M.
DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.
JNK-IN-7 is a relatively selective JNKs inhibitor(IC50= 1.54/1.99/0.75 for JNK1/2/3); also bound to IRAK1, PIK3C3, PIP5K3 and PIP4K2C.
JNK-IN-8 is a selective JNK1/2/3 inhibitor(IC50=4.67/18.7/0.98 nM) that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue.
SR-3306 is a brain penetrant small molecule JNK inhibitor from the aminopyrimidine class.